vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and PureCycle Technologies, Inc. (PCT). Click either name above to swap in a different company.

PureCycle Technologies, Inc. is the larger business by last-quarter revenue ($2.7M vs $1.8M, roughly 1.5× INVO Fertility, Inc.). INVO Fertility, Inc. runs the higher net margin — -150.5% vs -697.1%, a 546.6% gap on every dollar of revenue. INVO Fertility, Inc. produced more free cash flow last quarter ($-1.8M vs $-42.0M).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

PureCycle Technologies, Inc. is a sustainable materials firm with proprietary advanced polypropylene recycling technology. It converts contaminated polypropylene waste into high-purity virgin-equivalent resin for use in consumer goods, automotive parts, packaging and industrial products, serving global partners.

IVF vs PCT — Head-to-Head

Bigger by revenue
PCT
PCT
1.5× larger
PCT
$2.7M
$1.8M
IVF
Higher net margin
IVF
IVF
546.6% more per $
IVF
-150.5%
-697.1%
PCT
More free cash flow
IVF
IVF
$40.2M more FCF
IVF
$-1.8M
$-42.0M
PCT

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
IVF
IVF
PCT
PCT
Revenue
$1.8M
$2.7M
Net Profit
$-2.6M
$-18.8M
Gross Margin
Operating Margin
-93.1%
-2196.1%
Net Margin
-150.5%
-697.1%
Revenue YoY
22.6%
Net Profit YoY
-62.2%
71.0%
EPS (diluted)
$-0.77
$-0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
PCT
PCT
Q4 25
$2.7M
Q3 25
$1.8M
$2.4M
Q2 25
$1.9M
$1.6M
Q1 25
$1.6M
$1.6M
Q4 24
$1.7M
$0
Q3 24
$1.4M
$0
Q2 24
$1.8M
$0
Q1 24
$1.6M
$0
Net Profit
IVF
IVF
PCT
PCT
Q4 25
$-18.8M
Q3 25
$-2.6M
$-28.4M
Q2 25
$-5.3M
$-144.2M
Q1 25
$-17.4M
$8.8M
Q4 24
$-3.6M
$-64.7M
Q3 24
$-1.6M
$-90.6M
Q2 24
$-2.2M
$-48.2M
Q1 24
$-1.6M
$-85.6M
Gross Margin
IVF
IVF
PCT
PCT
Q4 25
Q3 25
Q2 25
Q1 25
35.2%
Q4 24
41.4%
Q3 24
31.0%
Q2 24
53.1%
Q1 24
45.3%
Operating Margin
IVF
IVF
PCT
PCT
Q4 25
-2196.1%
Q3 25
-93.1%
-1602.2%
Q2 25
-160.4%
-2763.5%
Q1 25
-1042.1%
-2387.4%
Q4 24
-202.0%
Q3 24
-90.7%
Q2 24
-100.9%
Q1 24
-95.7%
Net Margin
IVF
IVF
PCT
PCT
Q4 25
-697.1%
Q3 25
-150.5%
-1167.5%
Q2 25
-283.6%
-8741.8%
Q1 25
-1060.1%
559.0%
Q4 24
-211.3%
Q3 24
-113.8%
Q2 24
-122.2%
Q1 24
-101.3%
EPS (diluted)
IVF
IVF
PCT
PCT
Q4 25
$-0.14
Q3 25
$-0.77
$-0.31
Q2 25
$-13.30
$-0.81
Q1 25
$-12.53
$0.05
Q4 24
$14.86
$-0.40
Q3 24
$-15.11
$-0.54
Q2 24
$-22.39
$-0.29
Q1 24
$-7.55
$-0.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
PCT
PCT
Cash + ST InvestmentsLiquidity on hand
$156.7M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
$45.9M
Total Assets
$18.8M
$922.7M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
PCT
PCT
Q4 25
$156.7M
Q3 25
$234.4M
Q2 25
$284.1M
Q1 25
$22.5M
Q4 24
$15.7M
Q3 24
$83.7M
Q2 24
$10.9M
Q1 24
$25.0M
Total Debt
IVF
IVF
PCT
PCT
Q4 25
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IVF
IVF
PCT
PCT
Q4 25
$45.9M
Q3 25
$5.8M
$68.2M
Q2 25
$2.6M
$98.9M
Q1 25
$3.3M
$238.2M
Q4 24
$12.7M
$180.4M
Q3 24
$-23.3K
$241.4M
Q2 24
$1.4M
$291.6M
Q1 24
$10.2K
$336.8M
Total Assets
IVF
IVF
PCT
PCT
Q4 25
$922.7M
Q3 25
$18.8M
$989.1M
Q2 25
$19.3M
$1.0B
Q1 25
$31.7M
$787.3M
Q4 24
$46.4M
$798.4M
Q3 24
$17.0M
$788.8M
Q2 24
$17.8M
$719.8M
Q1 24
$17.3M
$734.0M
Debt / Equity
IVF
IVF
PCT
PCT
Q4 25
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
PCT
PCT
Operating Cash FlowLast quarter
$-1.8M
$-28.7M
Free Cash FlowOCF − Capex
$-1.8M
$-42.0M
FCF MarginFCF / Revenue
-101.6%
-1559.6%
Capex IntensityCapex / Revenue
0.5%
495.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M
$-183.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
PCT
PCT
Q4 25
$-28.7M
Q3 25
$-1.8M
$-38.5M
Q2 25
$-1.7M
$-36.7M
Q1 25
$-3.5M
$-38.9M
Q4 24
$-617.4K
$-31.8M
Q3 24
$-640.8K
$-33.4M
Q2 24
$-1.5M
$-40.4M
Q1 24
$-260.6K
$-39.2M
Free Cash Flow
IVF
IVF
PCT
PCT
Q4 25
$-42.0M
Q3 25
$-1.8M
$-42.4M
Q2 25
$-1.7M
$-45.3M
Q1 25
$-3.6M
$-53.9M
Q4 24
$-696.3K
$-53.4M
Q3 24
$-42.6M
Q2 24
$-1.5M
$-50.8M
Q1 24
$-310.3K
$-53.5M
FCF Margin
IVF
IVF
PCT
PCT
Q4 25
-1559.6%
Q3 25
-101.6%
-1743.1%
Q2 25
-92.6%
-2747.1%
Q1 25
-216.9%
-3409.6%
Q4 24
-40.6%
Q3 24
Q2 24
-82.3%
Q1 24
-19.7%
Capex Intensity
IVF
IVF
PCT
PCT
Q4 25
495.1%
Q3 25
0.5%
160.3%
Q2 25
0.5%
521.5%
Q1 25
0.9%
949.6%
Q4 24
4.6%
Q3 24
0.0%
Q2 24
3.0%
Q1 24
3.2%
Cash Conversion
IVF
IVF
PCT
PCT
Q4 25
Q3 25
Q2 25
Q1 25
-4.40×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons